Phase I trial of CPI-0610 in myeloma commences

The US company, Constellation Pharmaceuticals, has announced that it has initiated a new Phase I trial of its proprietary drug, CPI-0610, for the treatment of myeloma patients who have relapsed after at least one prior line of treatment. CPI-0610 is a small molecule that inhibits bromodomain and extra-terminal (BET) proteins which are involved in chromatin…

Details

Velcade retreatment approved for myeloma patients

The US Food and Drug Administration (FDA) has approved the use of Velcade for the retreatment of myeloma patients who have previously responded to Velcade treatment and relapsed at least six months following completion of prior Velcade treatment. The approval is based on the results of the Phase II RETRIEVE trial which showed an overall…

Details

Phase III trial of Kyprolis® for myeloma patients meets primary endpoint

Amgen, the US biopharmaceutical company and its subsidiary, Onyx Pharmaceuticals, have announced that interim analysis of their Phase III clinical trial ASPIRE for relapsed myeloma patients has met the primary endpoint of progression-free survival. The results showed that patients treated with Kyprolis (carfilzomib) in combination with Revlimid and dexamethasone demonstrated significantly longer progression-free survival (median 26.3…

Details

NICE issue new draft ‘no’ for Revlimid® at first relapse

The National Institute for Health and Care Excellence (NICE) has issued a second draft guidance not recommending the use of Revlimid for myeloma patients at first relapse who have previously received Velcade® and who are not eligible for high-dose therapy and autologous stem cell transplantation. The appraisal consultation document has outlined that Revlimid is not considered…

Details